Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Additional Strategic Funding for CartiHeal's Ongoing AGILI-C™ IDE Clinical Study

Posted on: 31 Jan 18

CartiHeal, developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, has secured a $2.5M investment from Bioventus, a global leader in orthobiologics – reflecting the growing interest in CartiHeal’s technology.

This press release features multimedia. View the full release here:

Bioventus’s $2.5M boost complements CartiHeal’s latest financing round, led by aMoon, together with Johnson & Johnson Innovation (JJDC Inc.), Peregrine Ventures, and Elron, bringing the total round to $21M.

The funding will focus on CartiHeal’s ongoing Agili-C IDE clinical study. Further to the trial's initiation 3 months ago, over thirty patients were already enrolled, according to enrollment rate forecasts.

CartiHeal CEO, Nir Altschuler: “This investment is a vote of confidence by an important orthobiologic strategic player. Bioventus joins our team of strategic investors who perceived the potential of the Agili-C implant. We are confident that Bioventus will bring substantial added value to CartiHeal.”

“Agili-C shows great promise to relieve osteoarthritis pain for a large patient population and we look forward following the pivotal trial to a successful culmination,” said Tony Bihl, CEO, Bioventus.

About CartiHeal

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.

About the Agili-C™ implant IDE multinational pivotal study

The Agili-C™ IDE study is set to include a minimum of 250 patients in US and OUS centers, aiming for a PMA submission. The trial's objective is to demonstrate the superiority of the Agili-C™ implant over the surgical standard of care (microfracture and debridement) for the treatment of cartilage or osteochondral defects, in both osteoarthritic knees and knees without degenerative changes.

About Bioventus

Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Orthobiologic products from Bioventus include offerings for bone healing, bone graft and knee osteoarthritis. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit and follow the company on Twitter @Bioventusglobal.

Bioventus and the Bioventus logo are registered trademarks of Bioventus, LLC.

View source version on

Business Wire

Last updated on: 31/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.